The 1 analysts offering 12-month price forecasts for Brooklyn Immunotherapeutics Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. The median estimate represents a +223.36% increase from the last price of 6.19.
The current consensus among 1 polled investment analysts is to Buy stock in Brooklyn Immunotherapeutics Inc. This rating has held steady since October, when it was upgraded from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.09
Reporting Date Mar 16
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.